These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 19879838)

  • 1. Tetherin inhibits HIV-1 release by directly tethering virions to cells.
    Perez-Caballero D; Zang T; Ebrahimi A; McNatt MW; Gregory DA; Johnson MC; Bieniasz PD
    Cell; 2009 Oct; 139(3):499-511. PubMed ID: 19879838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Neil SJ; Zang T; Bieniasz PD
    Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of HIV-1 virion entrapment by tetherin.
    Venkatesh S; Bieniasz PD
    PLoS Pathog; 2013; 9(7):e1003483. PubMed ID: 23874200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
    PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
    Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
    J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
    Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
    J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane.
    Hammonds J; Wang JJ; Yi H; Spearman P
    PLoS Pathog; 2010 Feb; 6(2):e1000749. PubMed ID: 20140192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
    Ali MS; Hammonds J; Ding L; Spearman P
    PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetherin: holding on and letting go.
    Sauter D; Specht A; Kirchhoff F
    Cell; 2010 Apr; 141(3):392-8. PubMed ID: 20434978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
    Lim ES; Malik HS; Emerman M
    J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetherin is as tetherin does.
    Hammonds J; Spearman P
    Cell; 2009 Oct; 139(3):456-7. PubMed ID: 19879831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetherin restricts productive HIV-1 cell-to-cell transmission.
    Casartelli N; Sourisseau M; Feldmann J; Guivel-Benhassine F; Mallet A; Marcelin AG; Guatelli J; Schwartz O
    PLoS Pathog; 2010 Jun; 6(6):e1000955. PubMed ID: 20585562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.